Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function

NCT04469920 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

98

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Impairment

Interventions

DRUG: Saroglitazar Magnesium 2 mg
DRUG: Saroglitazar Magnesium 4 mg

Sponsor

Zydus Therapeutics Inc.